Curated News
By: NewsRamp Editorial Staff
April 28, 2026

Helus Pharma Partners with TARA Mind and VETS to Boost Depression Trial Recruitment

Discuss on Substack Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • Helus Pharma's FDA Breakthrough Therapy for HLP003 positions it ahead in the major depressive disorder market.
  • Helus Pharma partners with TARA Mind and VETS to recruit veterans for its Phase 3 HLP003 trial targeting depression.
  • This collaboration expands mental health awareness and accelerates treatments for veterans suffering from depression.
  • Helus Pharma's novel serotonergic agonists aim to promote neuroplasticity, potentially transforming mental health treatment.

Impact - Why it Matters

This partnership is important because it directly addresses the mental health crisis among veterans, a population with disproportionately high rates of depression and suicide. By leveraging the trusted networks of TARA Mind and VETS, Helus Pharma can accelerate recruitment for its Phase 3 trial of HLP003, potentially bringing a breakthrough therapy to market faster. If successful, this treatment could offer a new option for millions suffering from major depressive disorder who have not responded to existing therapies, highlighting the critical need for innovation in mental health care.

Summary

Helus Pharma™ (NASDAQ: HELP), the commercial operating name of Cybin Inc., has announced a strategic collaboration with TARA Mind and Veterans Exploring Treatment Solutions (VETS) to support clinical trial recruitment for its PARADIGM HLP003 Phase 3 program. This program targets major depressive disorder (MDD) and aligns with the April 18, 2026 Executive Order on accelerating treatments for serious mental illness. The partnership leverages the networks of TARA Mind and VETS to enhance veteran engagement and raise mental health awareness within the veteran community.

Helus Pharma is advancing its FDA Breakthrough Therapy-designated HLP003 program, a proprietary novel serotonergic agonist (NSA) designed to activate serotonin pathways and promote neuroplasticity. The company is also developing HLP004, another NSA in Phase 2 for generalized anxiety disorder. With class-leading data, Helus aims to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions by providing durable improvements in mental health.

Founded in 2019, Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. The company's pipeline includes multiple investigational NSAs. For more information, visit the Helus Pharma newsroom or follow the team on social media. This collaboration underscores Helus's commitment to tackling serious mental illness and advancing innovative treatments for those in need.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Helus Pharma Partners with TARA Mind and VETS to Boost Depression Trial Recruitment

blockchain registration record for this content.